- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04486222
RTMS bilateral acelerada en la depresión geriátrica
Efecto terapéutico de la estimulación magnética transcraneal repetida bilateral acelerada en la depresión geriátrica: un ensayo prospectivo controlado, aleatorizado, doble ciego
This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety.
Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS.
In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Douliu, Taiwán
- Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- age between 60-85 years
- literate and received basic education for at least 2 years
- diagnosis of major depressive disorder, without psychotic features, according to DSM-5
- have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
- failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
- psychoactive agents were in stable doses before randomization
Exclusion Criteria:
- active suicide plans or attempts; or suicide attempts in the last 12 months
- diagnosis of schizophrenia or bipolar disorder according to DSM-5
- have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
- have delirium, major neurocognitive disorder or MMSE < 24
- current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
- history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
- with a cardiac pacemaker or defibrillator
- received rTMS treatment before
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Experimental Group
The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total. |
Magstim® Super Rapid² Transcranial Magnetic Stimulation System |
|
Comparador activo: Standard Treatment Group
The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total. |
Magstim® Super Rapid² Transcranial Magnetic Stimulation System |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Periodo de tiempo: day 1, day 5, day 12, day 19
|
HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17. |
day 1, day 5, day 12, day 19
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)
Periodo de tiempo: day 1, day 5, day 12, day 19
|
HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Mini-Mental State Examination (MMSE)
Periodo de tiempo: day 1, day 5, day 12, day 19
|
MMSE is a wildly-used tool to evaluate several cognitive function domains. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Stroop Test
Periodo de tiempo: day 1, day 5, day 12, day 19
|
Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue). |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Trail Making Test
Periodo de tiempo: day 1, day 5, day 12, day 19
|
Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Verbal Fluency Test
Periodo de tiempo: day 1, day 5, day 12, day 19
|
This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Physiological Parameters
Periodo de tiempo: day 1, day 5, day 12, day 19
|
ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured. |
day 1, day 5, day 12, day 19
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 201910101RIND
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .